Immunotherapy News and Research

Latest Immunotherapy News and Research

Catalan researchers first to use liposomes to fight against diabetes

For the first time liposomes that imitate cells in the process of natural death have been used to treat Diabetes. Researchers at Germans Trias Research Institute (at UAB-Campus of International Excellence Sphere) generated liposomes in collaboration with professionals from the ICN2. PLOS ONE Journal publishes the work.

10 Jun 2015

Massey researchers aim to develop models that can predict complications from stem cell transplantation

Researchers at VCU Massey Cancer Center's Bone Marrow Transplant Program have recently published findings from a phase 2 clinical trial that demonstrate lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival.

10 Jun 2015

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.

10 Jun 2015

OncoSec Medical reports net loss of $14.7 million for FY 2015

OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the nine months ended April 30, 2015.

9 Jun 2015

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced an independent data monitoring committee (IDMC) has recommended the continuation of the company’s pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) following the first of three planned interim data analyses.

5 Jun 2015

Penn Medicine researchers explore primary player involved in T cell exhaustion

Sometimes even cells get tired. When the T cells of your immune system are forced to deal over time with cancer or a chronic infection such as HIV or hepatitis C, they can develop 'T cell exhaustion,' becoming less effective and losing their ability to attack and destroy the invaders of the body.

4 Jun 2015

RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd‑rxRNA).

3 Jun 2015

Aushon BioSystems announces commercial release of Ultrasensitive Cira Assays

Aushon BioSystems, a leading provider of products and services for multiplex quantitative detection of protein biomarkers, today announced the commercial release of its Ultrasensitive Cira Assays capable of measuring concentrations of low abundance proteins down to the femtogram/mL level.

2 Jun 2015

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, over the weekend in Chicago released promising new data on their Phase I trial of DCVax-Direct for direct injection into all types of inoperable solid tumors.

2 Jun 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.

2 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

NSCLC treatment market forecast to reach $7.9 billion by 2020

The Non-Small Cell Lung Cancer treatment market will be driven primarily by the introduction of numerous premium therapies, particularly in second-line and squamous cell treatment settings, which either replace or combine with generic chemotherapies.

2 Jun 2015

Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Research led by Howard L. Kaufman, MD, FACS, associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey and colleagues, shows advanced-stage melanoma patients have significant improvement in durable response rate and a trend toward improved survival when treated with a genetically-modified form of a herpes virus, whose native form causes the common cold sore.

2 Jun 2015

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.

2 Jun 2015

Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), announces today positive preclinical in vivo proof of concept results of GTL002, its multivalent HPV therapeutic vaccine candidate based on the Company’s versatile Vaxiclase platform.

2 Jun 2015

Mount Sinai Health System researchers present updates on cancer vaccine clinical trials at ASCO 2015

Mount Sinai Health System faculty will be presenting research updates on a lymphoma vaccine clinical trial, the best dosing for a drug against metastatic cancer, and new treatment strategies in relapsed multiple myeloma at the American Society of Clinical Oncology annual meeting, May 29 - June 2, 2015, in Chicago.

2 Jun 2015

University of Southampton and BioInvent enter collaboration to develop new cancer immunotherapies

Leading antibody researchers at the University of Southampton, under the direction of Professor Mark Cragg, Professor of Experimental Cancer Research and Director of the Cancer Pathway Integrated Postgraduate Programme, today announce a three-year research collaboration with BioInvent International.

1 Jun 2015

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the results of a study identifying the clinical benefit of targeted therapy in colorectal cancer (CRC) with high microsatellite instability (MSI-H), a predisposition that occurs in 15% of all CRCs causing significantly different prognosis and response to treatment.

1 Jun 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone.

1 Jun 2015

Immunotherapy News and Research

Latest Immunotherapy News and Research

Catalan researchers first to use liposomes to fight against diabetes

Massey researchers aim to develop models that can predict complications from stem cell transplantation

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

OncoSec Medical reports net loss of $14.7 million for FY 2015

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Penn Medicine researchers explore primary player involved in T cell exhaustion

RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

Aushon BioSystems announces commercial release of Ultrasensitive Cira Assays

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

NSCLC treatment market forecast to reach $7.9 billion by 2020

Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

Mount Sinai Health System researchers present updates on cancer vaccine clinical trials at ASCO 2015

University of Southampton and BioInvent enter collaboration to develop new cancer immunotherapies

Caris Life Sciences: Study identifies benefit of targeted therapy in CRC with high microsatellite instability

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in